Snehitha Vijaykumar, MD
Interventional Cardiology · Ames, IANPI 1376960526
Payments from drug & device makers
What this record shows
This record is dominated by grants: $8,605 of the $13,534 with a category attached, or 63.6%. 22 manufacturers reported payments, led by Medtronic at 59.2% of the total. Reporting peaked in 2020 at $8,958 and has fallen 99.0% since, to $86 in 2025.
Across 118 payments — averaging $114.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$8K
- Abbott$2K
- Boston Scientific$1K
- Edwards Lifesciences$931
- Cardiovascular Systems Inc.$441
- Shockwave Medical, Inc$243
- plus $1K from 16 others
What the payments were for
- Grants$8,60564%
- Travel & lodging$1,0087%
- Food & beverage$3,62827%
- Education$2942%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 10 | $8,012 |
| Abbott | 30 | $1,594 |
| Boston Scientific | 7 | $1,172 |
| Edwards Lifesciences | 10 | $931 |
| Cardiovascular Systems Inc. | 16 | $441 |
| Shockwave Medical, Inc | 2 | $243 |
| Penumbra, Inc. | 2 | $240 |
| AstraZeneca | 3 | $154 |
| Cardinal Health 200 LLC | 5 | $147 |
| Amgen | 10 | $141 |
| Boehringer Ingelheim | 1 | $125 |
| Pfizer | 4 | $62 |
| Terumo Medical Corporation | 1 | $51 |
| Novartis | 3 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Johnson & Johnson | 1 | $28 |
| Philips North America LLC | 1 | $24 |
| Inari Medical, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,534 in reported general payments places this provider in the 75th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 195 | $174,759 |
| XareltoRivaroxaban | 31 | $34,166 |
| BrilintaTicagrelor | 35 | $26,295 |
| JardianceEmpagliflozin | 27 | $18,310 |
| EntrestoSacubitril/Valsartan | 12 | $13,881 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $3,478 |
| Ranolazine ErRanolazine | 19 | $3,162 |
| Metoprolol Succinate | 240 | $2,941 |
| Atorvastatin Calcium | 177 | $1,431 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 53 | $1,215 |
| Bumetanide | 15 | $778 |
| ClopidogrelClopidogrel Bisulfate | 95 | $631 |
| Losartan Potassium | 79 | $604 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 58 | $579 |
| Ezetimibe | 24 | $468 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $62 | $174,759195 claims |
| Johnson & JohnsonXarelto | $28 | $34,16631 claims |
| AstraZenecaBrilinta | $154 | $26,29535 claims |
| Boehringer IngelheimJardiance | $125 | $18,31027 claims |
| NovartisEntresto | $45 | $13,88112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Ames
- Suhas BhatAmes$457
- Nicolas ShammasDavenport$808K
- Eric DippelDavenport$100K
- Atul ChawlaDes Moines$78K
- Magdi GhaliWest Des Moines$64K
- David McAllisterDes Moines$55K
- Daniel ShivapourDes Moines$54K
- Srikanth KasulaDavenport$43K
- Abdulrahman AbdulbakiDes Moines$43K
- Jason AllenIowa City$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.